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Abemaciclib (Verzenio w ) is approved as a tyrosine kinase inhibitor (TKI) for breast cancer treatment. In this study, in vitro phase I metabolic profiling of Abemaciclib (ABC) was done using rat liver microsomes (RLMs). We checked the formation of reactive intermediates in ABC metabolism using RLMs in the presence of potassium cyanide (KCN) that was used as a capturing agent for iminium reactive intermediates forming a stable complex that can be characterized by LC-MS/MS. Nine in vitro phase I metabolites and three cyano adducts were identified. The metabolic reactions involved in the formation of these metabolites and adducts are reduction, oxidation, hydroxylation and cyanide addition. The bioactivation pathway was also proposed. Knowing the electrodeficient bioactive centre in ABC structure helped in making targeted modifications to improve its safety and retain its efficacy. Blocking or isosteric replacement of a-carbon to the tertiary nitrogen atoms of piperazine ring can aid in reducing toxic side effects of ABC. No previous articles were found about in vitro metabolic profiling for ABC or structural identification of the formed reactive metabolites for ABC. distant areas of the body [1] . Globally, breast cancer is the most frequently diagnosed cancer in women; it affects about 12% of women worldwide [2] . Saudi Arabia is no exception, where breast cancer is most commonly prevalent. It accounts for about 22% of all new cancers in women that are ranked first figures [3] . There is a group of novel drugs that specifically target gene changes in cancer cells that help the cells grow or spread. Tyrosine kinases (TKs) are important targets because of their important role in the modulation of growth factor signalling [4] . Controlling the activity of TK in the cell regulates many vital processes such as cell cycle, proliferation and cell death [5] .
Introduction
Cyclin-dependent kinases 4 and 6 (CDK4/6), as a class of tyrosine kinase inhibitor (TKI), play a crucial role in cell proliferation. When CDK4/6 pathway is dysregulated, it leads to an implication in breast cancer biology [6] . There are three highly selective CDK4/6 inhibitors that have been approved for breast cancer therapy: Palbociclib, Ribociclib and Abemaciclib (ABC) (Verzenio w ) [7] . ABC (figure 1) is the third agent in this class, which was approved in September 2017 by the Food and Drug Administration (FDA), either in combination with fulvestrant for women or as monotherapy for women and men with HR-positive, HER2-negative advanced or metastatic breast cancer. Lately, in February 2018, FDA approved ABC with an aromatase inhibitor as the first-line endocrine-based therapy for metastatic breast cancer. The most frequent side effects of the drug were diarrhoea, which occurred in approximately 80% of patients, neutropenia, fatigue, infections, nausea, abdominal pain, anaemia, vomiting, alopecia, decreased appetite and leukopenia [8] .
Our group previously studied reactive metabolite formations of some TKI drugs. The current work proved that ABC formed three reactive intermediates through a specific bioactivation pathway. KCN was used as a trapping agent to capture the formed reactive metabolites and the bioactivation pathways were characterized [8] [9] [10] [11] [12] . The chemical structures of ABC contain N-ethyl piperazine ring. This group is expected to undergo metabolism generating reactive iminium intermediates that can be trapped by KCN forming cyano adducts. Oxidation at a carbon alpha to an N-substituted piperazine ring is known to result in iminium ions, which are considered hard electrophiles and can be trapped by cyanide anions to form cyano adducts. The N-substituted piperazine partial structures become bioactivated and subsequently trapped by the nucleophilic cyanide anion. The reactive intermediates were postulated as imine and imine-carbonyl conjugate (a,b-unsaturated) structures on the piperazine ring. Bioactivation of the N-substituted piperazine partial structure, which can be characterized and detected using tandem mass spectrometry (LC-MS/MS), is a possible explanation for reported idiosyncratic toxicity [13] [14] [15] [16] .
Iminium intermediates initiate several toxic side effects through previously reported mechanisms as in the case of brigatinib and ponatinib that bind covalently to a DNA base [9, 17] . Knowing the electrodeficient bioactive centre in ABC structure helped in making targeted modifications to improve its safety and retain its efficacy. ABC rat liver microsome (RLM) incubation resulted in the identification of nine in vitro phase I metabolites and three cyano conjugates, and the proposed reactions involved include reduction, oxidation, hydroxylation and cyanide addition. 
Chromatographic conditions
An Agilent 6410 QQQ equipped with an ESI coupled to an Agilent 1200 HPLC was used. The liquid and mass chromatographic parameters were adjusted for each drug. ABC and its metabolites were produced in the collision cell by CID. The optimized conditions for chromatographic resolution of incubation mixture extract are given in table 2.
RLM incubations
ABC was incubated at 20 mM with 1 mg ml 21 RLMs, 1 mM NADPH, 1 mM KCN and 50 mM Na/K phosphate buffer ( pH 7.4) containing 3.3 mM MgCl 2 . The mixtures were incubated at 378C in a shaking water bath for 60 min before the metabolic reactions were terminated using protein precipitation by adding 2 ml of ice-cold ACN followed by centrifugation at 9000 g for 10 min at 48C. The supernatants were removed to clean vials then evaporated to dryness, reconstituted in the mobile phase and analysed by the LC/MS system [8, 12, 17, 20] . Two controls were done in the absence of NADPH or RLMs to confirm that ABC phase I metabolites were metabolically formed.
Characterization of ABC reactive intermediates in in vitro metabolic reactions
The same RLM metabolic incubation with ABC, previously described in §2.3, was repeated but in addition to 1.0 mM KCN to trap reactive iminium intermediates. This experiment was repeated three times to confirm the results and support our conclusions. Two controls were done in the absence of NADPH or KCN to confirm that cyano adducts are formed due to metabolic bioactivation.
Identification of ABC reactive metabolites
MS scan and extracted ion chromatogram (EIC) detection modes were used to characterize and locate metabolites in the incubation mixtures, while product ion (PI) was used to identify ABC in vitro metabolites and adducts of reactive intermediates formed in ABC metabolism. Locating metabolites in metabolic mixture extract chromatogram was performed by EIC of m/z of the supposed ABC metabolites.
3. Results and discussion 
Identification of in vitro and reactive ABC metabolites
After the purification and extraction of ABC RLM incubations, 15 ml was injected into LC-MS/MS. ABC incubation led to the identification of nine in vitro phase I metabolites and three cyano adducts, and the proposed reactions involved include reduction, oxidation, hydroxylation and cyanide addition ( 675  650  625  600  575  550  525  500  475  450  425  400  375  350  325  300  275  250  225  200  175  150  125  100  75  50 675  650  625  600  575  550  525  500  475  450  425  400  375  350  325  300  275  250  225  200  175  150  125  100  75  50 675  650  625  600  575  550  525  500  475  450  425  400  375  350  325  300  275  250  225  200  175  150  125  100  75 650  625  600  575  550  525  500  475  450  425  400  375  350  325  300  275  250  225  200  175  150  125  100  75  50 iminium intermediate and bioactivation mechanism of ABC was previously described with cyclic tertiary amine-containing drugs [10, 11, 17, 20] .
Conclusion
Three potential iminium reactive metabolites were detected and the bioactivation pathways were proposed ( figure 11 ). Nine in vitro phase I metabolites were identified. The findings of potentially reactive intermediates of these drugs may give a deeper understanding of their adverse effects.
Further drug discovery studies in ABC structure can shed more light on the possibility of blocking or reducing the formation of reactive intermediates by introducing alkyl substituents or isosteric replacement to the alpha position of the piperazine partial moiety which would probably block or interrupt enzymatic oxidation/hydroxylation on a-carbon atoms. This study opens the way for new drug development with more safety profile.
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